Firm Wire items are announcements made by the firms themselves. The desk confirms that the announcement was published and reproduces its factual content. It does not verify the claims in it, and publication is not an endorsement.
Morrison Foerster says it advised ViferaXS on funding of up to €12 million
Morrison Foerster said it advised biotechnology company ViferaXS on a Series A financing of up to €12 million, including grant funding. The firm said SPRIND and Huma led the financing alongside private investors, supporting the company’s development of treatments for hematological cancers.
Key points
- The firm said the funding supported the Phase II CLLTAXS01 study in chronic lymphocytic leukemia.Morrison Foerster
- Morrison Foerster also identified Phase I work involving acute myeloid leukemia and fibrolamellar carcinoma.Morrison Foerster
- The firm named counsel Monika Obal and partner Wolfgang Schönig on its team.Morrison Foerster
- The announcement also named Omid Ebrahimzadeh and Zoé Menkhoff as advisers.Morrison Foerster